Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: ODC1 and MYCN co-occurring amplification. (A) Neuroblastoma cell lines with distinct genomic profiles are shown: NBLS cells have neither MYCN nor ODC1 amplification, IMR5 has MYCN amplification (and ALK amplification, not shown), and KCN has both MYCN and ODC1 amplification; data represents Log R ratio output from lllumina Bead-Chip SNP arrays. (B) Fluorescence in situ hybridization (FISH) results for a primary neuroblastoma sample using probes for MYCN (2p24.3, red), ODC1 (2p25.1, aqua) and 2p centromere (CEN2, green) showing 4 CEN2 signals and amplification of both MYCN and ODC1 . Images courtesy of CHOP Division of Genomic Diagnostics (DGD).

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: Amplification, Fluorescence, In Situ Hybridization

Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: . Higher DFMO exposures are required to extend life in the TH-MYCN neuroblastoma model. TH-MYCN +/+ mice were randomized to ad libitum water (control) or water with 0.25 %, 0.5 % or 1 % DFMO added, from the time of birth onward. Mice taking 1 % DFMO had an extended overall survival compared to those taking 0.5 % DFMO or less; p < 0.001 by log-rank test; n = 20-25 mice/arm. Control versus 0.25 % DFMO, p = 0.80; control versus 0.5 % DFMO, p = 0.31).

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: Control

Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: DFMO-mediated translation effects. (A) Phospho-4EBP1 is not altered by DFMO (5 uM) but is reduced by the mTOR1/2 inhibitor, MLN0128 (100 μ M). (B) More sensitive IEF immunoblot confirms incomplete hypusination in most cell lines at higher DFMO exposures. (C) Dose response to DFMO for IMR5 and SK-N-BE2C cells (cells with higher proportion of non-hypusinated eIF5A in (B)). Cell line genomic status: M , MYC amplification; N , MYCN amplification; O , ODC1 amplification.

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: Western Blot, Amplification

Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: Puromycin incorporation by DFMO exposure in vitro. Puromycin incorporation was assessed across neuroblastoma cell lines of distinct MYCN and ODC1 gene status, as denoted. Densitometry was used to define relative change from vehicle control lanes; replicates are shown in line graph form with the immunoblots corresponding to the data from the circle-marked line. Cell line genomic status: M , MYC amplification; N , MYCN amplification; O , ODC1 amplification.

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: In Vitro, Control, Western Blot, Amplification

Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: Impact of AMXT-1501 and DFMO on puromycin incorporation. Puromycin incorporation was assessed across neuroblastoma cell lines of distinct MYCN and ODC1 gene status, as denoted, treated with both DFMO and AMXT-1501. Densitometry was used to define relative change from vehicle control lanes; replicates are shown in line graphs with the immunoblots corresponding to the data from the cirlce-marked line. Cell line genomic status: M , MYC amplification; N , MYCN amplification; O , ODC1 amplification.

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: Control, Western Blot, Amplification

Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: Colony Formation Assay across a range of DFMO exposures. Colony formation was assessed across neuroblastoma cell lines of distinct MYCN and ODC1 gene status, as denoted, treated with DFMO across a range of concentrations. Data represents replicate wells with representative well-images shown above. Cell line genomic status: M , MYC amplification; N , MYCN amplification; O , ODC1 amplification; *= p < 0.05, **= p < 0.01, ***= p < 0.001.

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: Colony Assay, Amplification

Journal: Neoplasia (New York, N.Y.)

Article Title: High-dose DFMO alters protein translation in neuroblastoma

doi: 10.1016/j.neo.2025.101215

Figure Lengend Snippet: ODC protein in response to DFMO exposure. (A, B) Treatment with DFMO leads to increased ODC protein levels by immunoblot across cell lines. (C) Dose response of IMR5 and CHLA136 cells to DFMO: ODC is increased at baseline in the ODC1- amplified cell line without significant increase in response to DFMO; shown as immunoblot and by densitometry relative to control lanes. Cell line genomic status: M , MYC amplification; N , MYCN amplification; O , ODC1 amplification.

Article Snippet: Primers: MTTP assay #Hs04877005_cn, ODC1 assay #Hs02651018_cn, and MYCN assay #Hs00201049_cn (Applied Biosystems), chosen for similar amplicon size (80-100 bps) for matched amplification efficiency.

Techniques: Western Blot, Amplification, Control